Expertise in
2
conditions

Roger M. Clarnette

8 Verdun St, 
Nedlands, WA, AU 
Expertise in
2
conditions
8 Verdun St, 
Nedlands, WA, AU 

Overview

Roger Clarnette practices practicing medicine in Nedlands, Australia.

Mr. Clarnette is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Alzheimer's Disease, Dementia, and Developmental Dysphasia Familial.

He is actively involved in clinical research, co-authoring 27 peer reviewed articles and participating in 6 clinical trials.

Gender

Male

Locations

8 Verdun St, Nedlands, WA 6009, Australia
Other Locations
35 Stirling Hwy, Crawley, WA 6009, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease
A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: July 27, 2026
Intervention Type: Drug
Study Drugs: Gantenerumab, Solanezumab
Study Phase: Phase 2/Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.
Enrollment Status: Completed
Publish Date: August 11, 2025
Intervention Type: Drug
Study Drug: CT1812
Study Phase: Phase 2
XanADu: A Phase II, Double-Blind, 12-Week, Randomised, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to Alzheimer's Disease (AD)
XanADu: A Phase II, Double-Blind, 12-Week, Randomised, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to Alzheimer's Disease (AD)
Enrollment Status: Completed
Publish Date: February 03, 2025
Intervention Type: Drug
Study Phase: Phase 2
Deferiprone to Delay Dementia (The 3D Study): a Clinical Proof of Concept Study
Deferiprone to Delay Dementia (The 3D Study): a Clinical Proof of Concept Study
Enrollment Status: Completed
Publish Date: July 03, 2024
Intervention Type: Drug
Study Drug: Deferiprone
Study Phase: Phase 2
Phase 1b Open-Label, Dose-Identification Study of XPro1595 in Patients With Alzheimer's Disease and Biomarkers of Inflammation.
Phase 1b Open-Label, Dose-Identification Study of XPro1595 in Patients With Alzheimer's Disease and Biomarkers of Inflammation.
Enrollment Status: Completed
Publish Date: June 15, 2023
Intervention Type: Drug
Study Drug: XPro1595
Study Phase: Phase 1
A Randomized, Placebo-Controlled, Translational Study of ATH-1017 in Subjects With Mild to Moderate Alzheimer's Disease
A Randomized, Placebo-Controlled, Translational Study of ATH-1017 in Subjects With Mild to Moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: June 12, 2023
Intervention Type: Drug
Study Drug: ATH-1017
Study Phase: Phase 2
View 5 Less Clinical Trials

27 Total Publications

Phase 3 randomized clinical trials of simufilam in mild-to-moderate Alzheimer's disease.
Phase 3 randomized clinical trials of simufilam in mild-to-moderate Alzheimer's disease.
Journal: The journal of prevention of Alzheimer's disease
Published: August 19, 2025

Frequently Asked Questions about Roger M. Clarnette

Is Roger M. Clarnette a top-rated expert for Alzheimer's Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Roger M. Clarnette is classified as an Advanced expert for Alzheimer's Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Roger M. Clarnette participate in research or clinical trials?

Yes. Roger M. Clarnette has published 27 articles and abstracts on conditions like Alzheimer's Disease. You can view a list of Roger M. Clarnette's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Clarnette's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile